# Role of Interferon lambda signaling in mucosal homeostasis and infantile-onset inflammatory bowel disease

> **NIH NIH K08** · BOSTON CHILDREN'S HOSPITAL · 2020 · $169,505

## Abstract

PROJECT SUMMARY/ABSTRACT
The gastrointestinal tract is composed of a single layer of epithelial cells that is in equipoise with immune cells
and a vast number of microorganisms. Inappropriate responses to these microorganisms, either through
genetic predisposition, altered immune or epithelial responses, or yet to be defined environmental influences,
are postulated to lead to inflammatory bowel diseases (IBD). The immune signals that recognize and respond
to bacterial and viral components of the microbiome remain incompletely understood. Interferons (IFNs) play a
major role in antiviral immune defense in the intestinal epithelium, and are also important in regulating
proliferation, differentiation, survival and effector functions of immune and non-immune cells. There are three
classes of IFNs: type I IFNs (IFNα, β, and others), type II IFN (IFNγ) and type III IFNs, or IFNλs. To date, most
studies investigating the use of IFNs on IBD have focused on type I IFNs and were not found to be effective.
Dr. Ivan Zanoni recently reported that IFNλ decreases oxidative stress and intestinal damage in a murine
model of colitis and that exogenous IFNλ can suppress intestinal inflammation. Importantly, we identified two
unrelated patients with infantile-onset IBD with rare and functionally deleterious mutations in IFNλ2 and IFNλ3.
Of note, each patient's disease improved significantly with age. We have preliminary data that IFNλ2 and
IFNλ3 may be more important in the first months of life than FNλ1, and data illustrating more severe murine
colitis in Ifnλ3-/- mice as compared to wild type mice. Taken together, we hypothesize that INFλs are
essential modulators of mucosal homeostasis, prevent development of IBD, and hold therapeutic
potential. Current therapeutics available for the management of IBD fail to treat a large number of patients.
This work will provide a better understanding of the role of IFNλ in mucosal homeostasis, and may provide the
groundwork to implement novel strategies to treat IBD by manipulating IFNλ signaling. Unraveling the role of
IFNλ in maintaining mucosal homeostasis will be achieved through the following aims: (1) Establishing the
developmental expression of IFNλs, related cytokines and receptors in humans at different ages using bulk
and single cell RNA sequencing technologies (2) Determining the role of IFNλ signaling in predisposition to
development of colitis in vivo using various murine models of colitis; (3) Characterizing the functional
consequences of patient-encoded IFNλ variants in vitro using T84 cells as well as human control and patient-
derived intestinal organoids. This award will enable Dr. Ouahed to acquire necessary structured training to
become proficient in critical skills: RNAseq analysis, murine models of colitis and immune analyses, and
generation/manipulation of intestinal organoids and epithelial analyses, complimented with didactic
coursework, assisting her path to independence as a successful physician-sci...

## Key facts

- **NIH application ID:** 9976675
- **Project number:** 1K08DK122133-01A1
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** Jodie Ouahed
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $169,505
- **Award type:** 1
- **Project period:** 2020-09-30 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9976675

## Citation

> US National Institutes of Health, RePORTER application 9976675, Role of Interferon lambda signaling in mucosal homeostasis and infantile-onset inflammatory bowel disease (1K08DK122133-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9976675. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*